Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alteplase for acute ischemic stroke.

Nicole R Gonzales1, James C Grotta

  • 1University of Texas, Houston Medical School, 6431 Fannin, MSB 7.118, Houston TX 7703, USA. Nicole.R.Gonzales@uth.tmc.edu

Expert Review of Cardiovascular Therapy
|May 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular Neurology Fellowship: Where Do We Go From Here?

Stroke·2026
Same author

Workplace Lactation in Neurology: Barriers and Opportunities.

Neurology. Clinical practice·2026
Same author

Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication.

Lancet (London, England)·2026
Same author

Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study.

Stroke·2026
Same author

CREST-2: Providing Clarity on Managing Asymptomatic Carotid Stenosis.

Stroke (Hoboken, N.J.)·2026
Same author

Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Alteplase (recombinant tissue plasminogen activator) is the sole FDA-approved treatment for acute ischemic stroke within 3 hours. It improves patient outcomes and is cost-effective, despite a risk of hemorrhage, and remains the first step in treatment.

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Acute ischemic stroke requires timely reperfusion therapy.
  • Alteplase (recombinant tissue plasminogen activator) is the only US FDA-approved thrombolytic for acute ischemic stroke within 3 hours of symptom onset.
  • Despite proven benefits, rt-PA remains underutilized in clinical practice.

Purpose of the Study:

  • To review the efficacy and safety of alteplase (rt-PA) in acute ischemic stroke.
  • To emphasize the importance of rt-PA as a primary treatment modality.
  • To discuss the cost-effectiveness and sustained benefits of rt-PA treatment.

Main Methods:

  • Review of existing clinical trial data and guidelines on rt-PA use in acute ischemic stroke.
  • Analysis of patient outcomes, including disability at 3 months and 1 year.

Related Experiment Videos

  • Assessment of safety profile, including symptomatic intracranial hemorrhage risk and mortality.

    • Main Results:

    • Patients treated with intravenous rt-PA show at least a 30% greater likelihood of minimal or no disability at 3 months compared to placebo.
    • rt-PA does not increase mortality, despite an increased risk of symptomatic intracranial hemorrhage.
    • The therapeutic benefits of rt-PA are cost-effective and sustained for at least 1 year post-treatment.

    Conclusions:

    • Alteplase (rt-PA) is a crucial and effective first-line treatment for acute ischemic stroke within the 3-hour window.
    • Establishing vessel recanalization remains the primary goal, with rt-PA being the initial step.
    • Future stroke management may involve multi-faceted approaches, but rt-PA's role is foundational.